Amsterdam Molecular Therapeutics reported that CEO Ronald Lorijn will retire from his position for personal reasons. Sander van Deventer, AMT's chief scientific officer and co-founder of the company, has been named interim CEO.

BaroFold has named J. William Freytag, Ph.D. as president and CEO.

Qiagen announced that Stephane Perrey joined the company as president of its fully-owned subsidiary Qiagen KK on January 1, 2009. He follows Kazuo Tokushige, who retired on December 31^st.

QRxPharma has appointed Jesus Soriano as its new executive vice president.

Gert-Jan Renardel de Lavalette has been hired as COO of OncoMethylome Sciences and Gerard Vaillant will join its board of directors as a replacement to Dr. Christian Schneider.

Alnylam Pharmaceuticals promoted Dr. Akshay Vaishnaw to senior vice president of clinical research.

Biological E. has hired three key executives. They are: Martin Reers, PhD, senior vice president, technical operations; Gopalam Somasekhar, PhD, senior vice president, development; and Krish Venkat, PhD, as senior vice president, quality.

Eden Biodesign announced a management restructuring to include the appointment of Dr. Derek Ellison as COO.

DxS has named Jeff Devlin as COO.

Halo Pharmaceutical has added Allen M. Rosenston as Halo's new vice president of business development.

Amylin Pharmaceuticals has appointed Vincent Mihalik as its new senior vice president of sales and marketing and chief commercial officer.

Pharmaceutical Strategic Initiatives has hired a new vice president of medical activities, Dr. Jeffrey New.

Cardium Therapeutics reported that Ronald I. Simon has retired from the company's board of directors.

AMAG Pharmaceuticals has named Robert J. Perez to its board of directors.

Bruce A. Peacock and Steven J. Burakoff, MD, have joined Ligand's board of directors.

Rudolph Nisi, MD has been appointed to RXi Pharmaceuticals' board of directors.

DOR BioPharma announced that president and CEO Christopher J. Schaber, PhD, has been elected to the board of directors of BioNJ.